Home About Us Pipeline News Investors Contacts Careers




Puma Biotechnology, Inc. Corporate Fact Sheet


RECENT NEWSCURRENT EVENTSCLINICAL TRIALS



January 6, 2017 - Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients
Read

January 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read

December 19, 2016 - Puma Biotechnology to Move Stock Exchange Listing to Nasdaq
Ticker symbol to remain PBYI
Read

December 8, 2016 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 7, 2016 - Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States

Caligor Opco LLC to provide regulatory, logistical and supply chain support Read

November 14, 2016 - Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

November 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results
Read

October 31, 2016 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

October 25, 2016 - Puma Biotechnology Closes $172 Million Public Offering of Common Stock
Read

October 21, 2016 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Share
Read

October 19, 2016 - Puma Biotechnology Prices Public Offering of Common Stock
Read

October 18, 2016 - Puma Biotechnology Announces Proposed Public Offering of Common Stock
Read

September 20, 2016 - Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

August 22, 2016 - Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

August 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results
Read

July 21, 2016 - Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)
Read

July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
Read

June 27, 2016 - Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
Read
January 10, 2017 - J.P. Morgan 2017 Healthcare Conference

December 6-9, 2016 - Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS)

More

Puma-Sponsored Trials
Investigator-Sponsored Trials




Annual Report

2015 Annual Report

 Annual Report Archives



Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
info@pumabiotechnology.com